Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication

Yasutake Shinohara; Toshie Iijima; Shintaro Sakurai; Teruo Jojima; Eriko Ohira; Shujiro Hayashi; Isao Usui; Ken Igawa; Yoshimasa Aso

doi:10.1002/ccr3.3047

Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication

Clin Case Rep. 2020 Aug 30;8(10):2007-2012. doi: 10.1002/ccr3.3047. eCollection 2020 Oct.

Authors

Yasutake Shinohara¹, Toshie Iijima¹, Shintaro Sakurai¹, Teruo Jojima¹, Eriko Ohira¹, Shujiro Hayashi², Isao Usui¹, Ken Igawa², Yoshimasa Aso¹

Affiliations

¹ Department of Endocrinology and Metabolism Dokkyo Medical University Tochigi Japan.
² Department of Dermatology Dokkyo Medical University Tochigi Japan.

Abstract

We experienced two cases of dipeptidyl peptidase-4 (DPP-4) inhibitor-associated bullous pemphigoid (BP) showing an unfavorable course despite its discontinuation. Clinicians should carefully monitor the course of DPP-4 inhibitor-associated BP even after withdrawal of DPP-4 inhibitor therapy, especially in very elderly patients.

Keywords: bullous pemphigoid; dipeptidyl peptidase‐4 inhibitor; type 2 diabetes.

Publication types

Case Reports